


Ameristem Revenue
Biotechnology Research • Houston, Texas, United States • 1-10 Employees
Ameristem revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Key Contact at Ameristem
Michael Blight
Director of Business Development
Company overview
| Headquarters | 10901 Katy Frw, Houston, TX 77079, US |
| Websites | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Dental Pulp Stem Cells |
| Founded | 2005 |
| Employees | 1-10 |
About Ameristem
Ameristem... Celebrating the power of life. Ameristem proprietary technology enables recovery of the most potent stem cells from dental pulp - Immature Dental Pulp Stem Cells (IDPSC). Stem Cell therapy is destined to become an important part of medicine in the near future. Immature Dental Pulp Stem Cells were discovered in 2004 by Ameristem's founders Dr. Alexander Kerkis and Dr. Irina Kerkis . In animal experiments, Immature Dental Pulp Stem Cells, have been found to contribute to virtually every tissue. IDPSC are unmatched in the speed of prolifiration, ease of harvesting and handling, and their ability to repair damaged tissues. Immature Dental Pulp Stem Cells can only be harvested using a proprietary technology - dental pulp organ culture - developed by Ameristem founders. Even if you have already preserved your child's cord blood, preserving IDPSC's is greatly recommended due to the possible benefits they offer over cord blood cells.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
Ameristem has never raised funding before.
Frequently asked questions
4.8
40,000 users



